Amino acid transporter Asc-1 (SLC7A10) expression is altered in basal ganglia in experimental Parkinsonism and L-dopa-induced dyskinesia model mice.
Mice
Animals
Levodopa
/ pharmacology
Dopamine
/ metabolism
Amino Acid Transport System ASC
/ metabolism
Receptors, N-Methyl-D-Aspartate
/ metabolism
Basal Ganglia
/ metabolism
Parkinsonian Disorders
/ metabolism
Parkinson Disease
/ metabolism
Dyskinesias
/ etiology
RNA, Messenger
/ metabolism
Serine
/ therapeutic use
Amino Acid Transport System y+
/ metabolism
6-hydroxydopamine (6-OHDA)
Amino acid transporter Asc-1 (SLC7A10)
Basal ganglia
L-dopa-induced dyskinesia (LID)
Laser microdissection
Parkinson's disease (PD)
Journal
Journal of chemical neuroanatomy
ISSN: 1873-6300
Titre abrégé: J Chem Neuroanat
Pays: Netherlands
ID NLM: 8902615
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
07
09
2022
revised:
13
11
2022
accepted:
15
11
2022
pubmed:
21
11
2022
medline:
4
1
2023
entrez:
20
11
2022
Statut:
ppublish
Résumé
In Parkinson's disease (PD), a decrease in dopamine levels in the striatum causes abnormal circuit activity in the basal ganglia, resulting in increased output via the substantia nigra pars reticulata (SNr). A characteristic feature of glutamatergic synaptic transmission in the basal ganglia circuitry under conditions of dopamine depletion is enhanced synaptic activity of NMDA receptors. However, the cause of this NMDA receptor hyperactivity is not fully understood. We focused on Asc-1 (SLC7A10), an alanine-serine-cysteine transporter, as one of the factors that regulate NMDA receptor activity by modulating D-serine and glycine concentration in synaptic clefts. We generated PD model mice by injection of 6-hydroxydopamine into the unilateral medial forebrain bundle and analyzed the expression level of Asc-1 mRNA in the nuclei of basal ganglia (the external segment of the globus pallidus (GPe), subthalamic nucleus (STN), and SNr) compared to control mice. Each nucleus was dissected using laser microdissection, and RNA was extracted and quantified by quantitative PCR. Asc-1 mRNA expression was significantly higher in the GPe and lower in the SNr under the PD state than that in control naïve mice. The STN showed no change in Asc-1 mRNA expression. We further modeled L-dopa-induced dyskinesia by administering L-dopa continuously for 14 days to the PD model mice and found that Asc-1 mRNA expression in the GPe and SNr became close to that of control mice, regardless of the presence of abnormal involuntary movements. The present study revealed that Asc-1 mRNA expression is differentially regulated in the basal ganglionic nuclei in response to striatal dopamine concentration (depleted or replenished) and suggests that Asc-1 can be a therapeutic target for the amelioration of motor symptoms of PD.
Identifiants
pubmed: 36403747
pii: S0891-0618(22)00121-1
doi: 10.1016/j.jchemneu.2022.102191
pii:
doi:
Substances chimiques
Levodopa
46627O600J
Dopamine
VTD58H1Z2X
Amino Acid Transport System ASC
0
Receptors, N-Methyl-D-Aspartate
0
RNA, Messenger
0
Serine
452VLY9402
Slc7a10 protein, mouse
0
Amino Acid Transport System y+
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102191Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Competing interests The authors declare that they have no competing interests.